Kornimate/medical-research-clean huggingface dataset:
influence of intravitreal aqueous tamponade on lens status and ocular

Conditions: Aqueous Tamponade; Cataract

Summary: to observe the effects of vitreous cavity balanced salt solution (bss) tamponade on the state of the lens and related parameters of the eye, and whether the changes of the above parameters are correlated with age, gender, diabetes or not, etc., so as to provide references for the diagnosis and treatment of related diseases and scientific research.


Eligibility criteria:
inclusion criteria: * ① patients undergoing vitrectomy for diabetic retinopathy, epiretinal membranes, macular hole, retinal detachment, and other diseases; * patients who underwent vitreous silicone oil tamponade and vitreous silicone oil removal due to various causes; ③ intraoperative bss was used for fill the vitreous cavity; ④ before treatment, inform the patient that the clinical data may be used in clinical research, and the patient and his family are informed and sign the informed consent. exclusion criteria: * ① the operation eye was intraocular lens or cataract extraction during operation; ② suspensory ligament relaxation or rupture, ciliary body detachment or transaction, lens dislocation, endophthalmitis, traumatic cataract; * intraoperative lens injury; ④ patients who refused to participate in the study.

Keywords: aqueous tamponade cataract lens thickness axial length pars plana vitrectomy
obturator nerve block with femoral and sciatic block

Conditions: Nerve Block; Pain Medication

Summary: the purpose of this study is to evaluate how many patients require the addition of the obturator nerve block in the recovery room after the total knee surgery. also to study the efficacy of blocking the obturator nerve in controlling their knee pain.


Eligibility criteria:
inclusion criteria: * total knee replacement exclusion criteria: * hisory of neurologica disease, diabetes, pregnancy, neuropathy
endoscopic ultrasound (eus)-guided ablation of pancreatic cysts

Conditions: Pancreatic Cyst; Pancreatic Intraductal Papillary-Mucinous Neoplasm; Cystadenoma, Mucinous; Papillary Mucinous Cystadenoma, Borderline Malignancy

Summary: the purpose of this study is to track outcomes and complications of patients at iumc referred by physicians for eus-guided pancreatic cyst ablation. this information is essential in order to disseminate future published information to physicians about this technique. a database will be created to track these patients undergoing an already scheduled/planned procedure. phone calls at selected intervals will be made following the procedure to track any complications that occur

pancreatic cysts represent a wide spectrum of lesions. many cysts are uniformly benign (pseudocysts) or have negligible malignant potential (serous cystadenomas). however, others represent premalignant (i.e. intraductal papillary mucinous neoplasms (ipmns) or mucinous cystadenomas \[mcn\]), or malignant (i.e. invasive ipmns or mucinous cystadenocarcinomas) tumors. management of pancreatic cysts is challenging but surgery is generally recommended for cysts that are symptomatic, premalignant (except possibly branch duct ipmns) or demonstrate malignancy by imaging features and/or biopsy. however, even in experienced hospitals, surgical resection or enucleation of pancreatic cystic tumors is associated with significant perioperative morbidity and mortality rates of 20-40% and up to 2%, respectively.

Eligibility criteria:
inclusion criteria: 1. patients referred between january 2009 and february 2016 to eus at iumc for pancreatic cyst ablation and with no contraindications for anticipated safe and successful performance of the procedure. 2. patient at least 18 years of age. exclusion criteria: 1. investigator deems cyst does not meet safety or need for cyst ablation. 2. subject not competent to sign consent

Keywords: intraductal papillary mucinous neoplasms (ipmns) mucinous cystadenomas [mcn]) invasive ipmns or mucinous cystadenocarcinomas) tumors
a safety study of of ag-920 sterile topical ophthalmic solution

Conditions: Anesthesia, Local

Summary: a phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. it is designed to evaluate the ocular safety of a single topical ocular administration of ag-920 sterile topical ophthalmic solution compared to placebo..

a phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects performed in the us. it is designed to evaluate the ocular safety of one dose of ag-920 compared to placebo. i). in this study, subjects who provide informed consent and fulfill all the inclusion criteria and none of the exclusion criteria will be randomized in a 2:1 ratio to receive one dose of ag-920 or identical looking placebo into one (study) eye. a subset of subjects will undergo endothelial cell count (ecc) evaluations. each dose of ag-920 or placebo will consist of two drops in the study eye. after the completion of dosing, subjects will undergo a series of eye exams that will be documented. investigational medicinal product (imp) dosing will be performed by the study staff.

Eligibility criteria:
inclusion criteria: 1. provide written informed consent prior to any study-related procedures being performed. 2. male or a non-pregnant, non-lactating female. 3. healthy by clinical assessment, including ocular examination. 4. have an early treatment of diabetic retinopathy study (etdrs) best corrected visual acuity (bcva) of 20/200 or better in both eyes. 5. have an intraocular pressure (iop) between 7 and 30 mmhg. specular microscopy subset subjects only: 6. have a central corneal endothelial cell density of ≥1500 cells/mm2 at baseline exclusion criteria: 1. . have participated in an investigational study within the past 30 days. 2. have a contraindication to local anesthetics, septocaine®, or any component of the imp. 3. have had ocular surgery or general surgery in either eye within the past 90 days. 4. have had an intravitreal injection in either eye within 14 days of randomization. 5. have ocular surface disease requiring punctal plugs. 6. have evidence of any current ocular inflammation. 7. current ocular allergy symptoms. 8. have used topical, ocular medications in the 24 hours preceding dosing. 9. systemic opioid, opiate analgesic or topical non-steroidal anti-inflammatory drug (nsaid) use within the past 30 days. 10. previous participation in a clinical study of ag-920. 11. a current condition which could cause vision problems such as pseudotumor cerebri.

Keywords: ag-920 articaine septocaine
solitaire™ fr with the intention for thrombectomy (swift) study

Conditions: Ischemic Stroke

Summary: the purpose of this study is to demonstrate substantial equivalence of the solitaire™ fr revascularization device (solitaire™ device) with a legally marketed device, merci retrieval system® (merci® device). the study will demonstrate safety and efficacy of the solitaire™ device in subjects requiring mechanical thrombectomy diagnosed with acute ischemic stroke.


Eligibility criteria:
inclusion criteria: * patient or patient's legally authorized representative has signed and dated an informed consent form * age22-85 * clinical signs consistent with acute ischemic stroke * national institutes of health stroke scale (nihss) ≥8and\<30 * thrombolysis in myocardial infarction (timi) 0 or timi 1 flow in the m1 or m2 of middle cerebral artery, internal carotid artery, basilar or vertebral arteries confirmed by angiography that is accessible to the solitairetm or merci® device * patient is able to be treated within 8 hours of stroke symptoms onset with minimum of one deployment of the solitairetm or merci® device. * patient who is ineligible or failed intravenous tissue plasminogen activator (t-pa) therapy given at local institutions or within national practice. * patient is willing to conduct follow-up visits exclusion criteria: * nihss \> 30 or coma * neurological signs that are rapidly improving prior to or at time of treatment * females who are pregnant or lactating * known serious sensitivity to radiographic contrast agents * current participation in another investigation drug or device study * uncontrolled hypertension defined as systolic blood pressure \> 185 or diastolic blood pressure \> 110 that cannot be controlled except with continuous parenteral antihypertensive medication * use of warfarin anticoagulation with international normalized ratio (inr) \> 3.0 * platelet count \< 30,000 * glucose \< 50 mg/dl * arterial tortuosity that would prevent the device from reaching the target vessel * life expectancy of less than 90 days * computed tomography (ct) or magnetic resonance imaging (mri) evidence of hemorrhage on presentation * ct showing hypodensity or mr showing hyperintensity involving greater than 1/3 of the middle cerebral artery (mca) territory (or in other territories, \>100 cc of tissue) on presentation * ct or mri evidence of mass effect or intracranial tumor (except small meningioma) * angiographic evidence of carotid dissection, complete cervical carotid occlusions, or vasculitis

Keywords: ischemic stroke solitaire™ device solitaire™ merci® device merci® stroke ischemic mechanical thrombectomy brain brain clot brain artery revascularization recanalization brain stroke clot retriever device neurosurgery neurovascular intervention interventional neuroradiology brain study neurovascular clinical trial
stereotactic body radiation for consolidation after standard chemoradiation for stage 3 lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to evaluate the efficacy and toxicity stereotactic body radiation (sbrt) as consolidation following standard chemoradiation for patients with stage iii non-small cell lung cancer.

this protocol will investigate the potential role of sbrt for patients with stage 3 nsclc. eligible patients will first have received standard 50.4 gy chemoradiation. patients entering the study will have the opportunity to receive sbrt as a noninvasive option as compared to surgical resection. for patients who are not surgical candidates, sbrt after 50.4 gy chemoradiation represents a technique of radiation consolidation that may be more effective and less toxic than standard conventional fractionated radiation

Eligibility criteria:
patient eligibility conditions for patient eligibility (inclusion) * pathologically or cytologically confirmed nsclc * stage iii nsclc according to the ajcc 7th edition staging criteria. stage ii (t1-3n1) patient that are deemed medically inoperable are also eligible. * concurrent chemoradiation to a radiation dose of 50.4 gy. * residual tumor volume after concurrent chemoradiation that is appropriate for sbrt: * primary tumor \<120cc (approximately 6cm diameter). * mediastinal/hilar disease: 1-2 involved regions \<60cc (approximately 5cmx3cmx3cm) * absolute neutrophil count ≥ 1,000/ul, platelet ≥ 60,000/ul. * total bilirubin ≤ 2x upper institutional limit of normal (uln), and ast or alt ≤5x uln. * ecog performance status 0 to 2 * minimum life expectancy of 12 weeks. * age older than 18 years. * voluntary, signed written informed consent. * women of childbearing potential must have a negative pregnancy test * men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 1 months thereafter. conditions for patient ineligibility (exclusion) * disease progression during or after standard chemoradiation to 50.4 gy * prior thoracic radiation other than the pre-operative radiation not greater than 50.4 * metastatic disease * uncontrolled severe, intercurrent illness. * women who are breast-feeding. * no chemotherapy within 2 weeks from the first sbrt treatment. * concurrent anticancer therapy. * prior complete resection of all nsclc.

Keywords: lung cancer
cesarean 123 trial: randomized trial comparing single, double and triple layer uterine closures during cesarean delivery

Conditions: Pregnancy Related

Summary: the goal of this clinical trial is to compare post-operative uterine scar thickness in people who have had the uterus closed during cesarean sections by one of three different methods. the main questions it aims to answer are: * residual myometrial thickness at the scar site assessed by mri performed 4 months after the procedure * myometrial niche formation assessed by mri performed 4 months after the procedure * scar healing ratio (hr) difference as defined by hr= residual myometrial thickness/total myometrial thickness * post-operative change in hemoglobin * time required for hysterotomy closure * the number of extra sutures required to achieve surgeon-acceptable hemostasis participants undergoing scheduled cesarean sections will be randomized to one of three different uterine closure methods. the methods are: 1. single layer closure using the following technique: closure of the myometrium and serosa with one barbed suture using a running unlocked technique. the endometrium should be excluded. 2. double layer closure using the following technique: closure of the full thickness of the myometrium with one smooth suture using a running locked technique. the endometrium should be excluded. followed by imbrication of the second layer with one smooth suture using a running unlocked technique. 3. triple layer closure of endometrium, myometrium and serosa (ems) using one of the the following two techniques: closure of the endometrium and 2-4 mm of internal myometrium with one barbed suture using a running unlocked technique followed by closure of the remaining myometrium and serosa with one barbed suture using a running unlocked technique. or, closure of the endometrium and 2-4 mm of internal myometrium with one barbed suture on using a running unlocked technique followed by closure of the remaining myometrium with one barbed suture a running unlocked technique followed by closure of the serosa with one barbed suture using a running unlocked technique. four months after the surgery, participants will have a mri of the pelvis to assess the scar on the uterus.


Eligibility criteria:
inclusion criteria: * 18 years or older * singleton gestation * nonurgent primary or secondary cesarean delivery at greater than 35w6d * body mass index (bmi) \<35 kg/m\^2 exclusion criteria: * more than 1 prior cesarean delivery * multiple gestation * known coagulation disorder or current use of anti-coagulants * mullerian anomalies * placenta previa

Keywords: cesarean myometrium scar thickness niche
effect of allergen challenge on inflammation induced by toll-like receptor stimulation in a nasal model

Conditions: Asthma

Summary: asthma is one of the most common diseases affecting about 2.5 million canadians, and can result in reduced quality of life and difficulties with work and school. once the disease has become established with irreversible changes in the lungs it can be very difficult to treat. severe asthma although less common than mild asthma uses more healthcare resources. the objective of this project is to find out how the changes in the lung develop in severe asthma. once this is known then new treatments can be developed to prevent irreversible damage to the lungs. volunteers will have substances sprayed up their nose and then samples collected from their nose. levels of proteins and cells can be measured in these samples. this will give an indication of the type of inflammation that occurs. the usual method of investigating the changes that occur in asthma is to challenge the lungs. samples have to then be collected from the lungs. this can be in the form of sputum which must be treated to break it down to a liquid or washed out during a camera test. these methods cause problems with measuring proteins and they are broken down or diluted. because the nose is easily accessible samples can be obtained at many time points. because the samples can be collected directly from the nose the problems with obtaining samples from the lung are avoided.


Eligibility criteria:
inclusion criteria: * 1 subjects over the age of 18 2 subjects able to give written informed consent 3 subjects able to comply with study procedures and protocol 4 subjects with a history of allergic asthma 5 subjects with a positive skin prick test to a common aeroallergen 6 subjects who are otherwise healthy with no other health problems exclusion criteria: 1. subjects with a viral urti within 2 weeks prior to screening. 2. subjects with a tnss\> 2 at screening 3. subjects with a structural nasal abnormality or nasal polyps on examination, a history of frequent nose bleeding, nasal surgery within the previous 3 months. 4. subjects who are a current smoker or have a history of smoking within the previous 3 months. 5. subjects who have used a medication that could affect responses to nasal challenge (eg corticosteroids, decongestants, anti-histamines) or any other nasally applied medication within 2 weeks prior to screening. 6. subjects who have participated in any other clinical trials within the previous 3 months. -

Keywords: nasal allergen lipopolysaccharide inflammation asthma
case management alternatives for african american women at high risk for hiv

Conditions: HIV

Summary: the purpose of this study is to test two innovative case management approaches designed to increase linkages and engagement with drug abuse treatment, hiv-related care, and other health services among an underserved population of african american women at risk for hiv.

the study is fundamentally concerned with the implementation and evaluation of theoretically-based, culturally appropriate case management interventions targeting individual, social and environmental factors among highly vulnerable african american women. the research is designed to test innovative, comprehensive approaches to hiv prevention/intervention through case management driven service linkage and engagement. testing new approaches to intervention with african-american women at high risk for hiv addresses a particularly urgent public health need in miami, as well as other large metropolitan areas, where officials continue to document epidemic rates of hiv/aids clustered in urban, impoverished african-american communities. comparison: participants will be randomly assigned to: a strengths-based / professional only condition in which clients participate in a "strengths-based" case management approach; or, a strengths-based / professional/peer condition in which a team composed of: a) a credentialed, professional case manager and b) a recovering addict peer - both trained in "strengths-based" case management techniques - develop and facilitate the implementation of a service plan.

Eligibility criteria:
inclusion criteria: * current substance abuse * current high-risk sexual behavior * african american racial identification exclusion criteria: * non resident of miami-dade county

Keywords: hiv/aids african americans women case management
famotidine in subjects with non-erosive gastroesophageal reflux disease

Conditions: Gastroesophageal Reflux

Summary: gastroesophageal reflux disease (gerd) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents. while most of the patients given the diagnosis of gerd do not exhibit endoscopically obvious impairment in esophageal mucous membrane, they have subjective symptoms of non-erosive gerd including heartburn. but no drug has been launched in japan, which targets non-erosive gerd. this study will examine the efficacy and safety of famotidine in subjects with non-erosive gerd.


Eligibility criteria:
inclusion criteria: * patients have heartburn with non-erosive gastroesophageal reflux disease. exclusion criteria: * patients have diseases which interfere with evaluation of the efficacy and safety in this study. * patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study. * patients have severe cardiovascular, hepatic, renal and hematological disorders. * patients are allergic to or have a history of drug allergy to h2ra. * patients have or have a history of malignant tumors. * patients are pregnant or a lactating mother. * patients have participated in other clinical studies less than 12 weeks prior to submitting the informed consent.

Keywords: treatment efficacy treatment effectiveness gastrointestinal diseases reflux, gastroesophageal gerd
presbyopia-correcting intraocular lenses (iols)

Conditions: Cataract

Summary: the purpose of this study is to prospectively evaluate postoperative visual and refractive parameters in a series of subjects bilaterally implanted with presbyopia-correcting intraocular lenses (iols).


Eligibility criteria:
inclusion criteria: * diagnosed with bilateral cataracts * candidate for presbyopic lens exclusion criteria: * \> 1 diopter preoperative astigmatism by keratometry readings * pre-existing conditions that could skew the results

Keywords: restor +3
virtual reality on pain, stress, and affect in the infusion clinic

Conditions: Cancer; Chemotherapy

Summary: this study will investigate the ability of virtual reality to function as a novel distraction intervention and improve the experience of patients who are receiving chemotherapy in the infusion clinic.

objectives: primary objective: - to deploy and evaluate virtual reality as an intervention for stress, pain, and negative affect secondary objective: - to evaluate cyber sickness and patient satisfaction related to the virtual reality treatment

Eligibility criteria:
inclusion criteria: * at or above the age of 18 * english speaking * diagnosed with cancer * no previous history of seizures, losses of awareness, or other symptoms linked to an epileptic condition * not sensitive to motion sickness * not currently experiencing any contagious conditions, infections, or diseases (particularly of the eyes, skin, or scalp) * does not use a device to regulate heart rate or rhythm (such as a pacemaker) * not taking antiarrhythmic medications * not actively receiving radiopharmaceutical therapy exclusion: * to ensure that there is sufficient time to complete the virtual reality treatment, patients who are scheduled for visits for periods of less than one hour will not be included in this study. additionally, patients must consent to participating in the study on the day of the experience. * patients who are asleep prior to consenting will not be asked to participate in the study
abdominal wall evaluation in low back pain

Conditions: Abnormally Decreased Muscle Contraction

Summary: the purpose of this study was to evaluate feed-forward contraction of the transversus abdominis and thickness of the transversus abdominis, obliquus internus, and obliquus externus during calm and standardized respiration in low back pain patients and pain-free subjects.

low back pain patients have alterations in abdominal wall function, especially in the feed-forward activation of transversus muscle during limbs movements. however, there are no reports on the abdominal function in low back pain patients during physiological respiratory movement.

Eligibility criteria:
inclusion criteria: * for the low back pain group: women with history of non-specific chronic low back pain for more than three months * for the pain-free group: pain-free women exclusion criteria: * for both groups were: pregnancy, neurological condition, obesity (body mass index: bmi \>30), or previous spine or abdominal surgery. * for the low back pain group: rheumatology diseases other than low back pain. * for the pain-free group: any rheumatology disease.